CD4+ T-cell reconstitution reduces cytomegalovirus in the immunocompromised brain

Jon D Reuter1, Jean H Wilson, Kimberly E Idoko

  • 1Section of Comparative Medicine, Yale University School of Medicine, New Haven, CT 06510, USA. jon.reuter@yale.edu

Journal of Virology
|July 15, 2005
PubMed

Insights

Adoptive transfer of Cytomegalovirus (CMV)-immune T cells effectively treats and prevents neurotropic CMV infection in the brain. This approach rapidly clears virus and prevents its entry into the central nervous system in immunocompromised models.

Area of Science:

  • Neuroimmunology
  • Infectious Diseases
  • Immunotherapy

Background:

  • Cytomegalovirus (CMV) is a common opportunistic central nervous system infection in immunocompromised individuals.
  • CMV infections can be refractory to treatment, leading to significant morbidity and mortality.
  • Current treatments for neurotropic CMV infection have limitations.

Purpose of the Study:

  • To investigate adoptive transfer of T cells as a strategy to treat and prevent neurotropic CMV infection.
  • To evaluate the efficacy of CMV-specific T cells in clearing viral infection within the brain.
  • To assess the ability of adoptive T-cell transfer to prevent CMV entry into the central nervous system.

Main Methods:

  • Severe combined immunodeficient (SCID) mice were infected intracranially with murine CMV (MCMV).
  • Mice were reconstituted with splenocytes or T cells sensitized to MCMV or vesicular stomatitis virus (VSV).
  • T cell migration to the brain and viral clearance were monitored using labeled cells and viral load assays.

Main Results:

  • CMV-immune T cells, particularly CD4+ T cells, rapidly crossed the blood-brain barrier and localized to infected brain regions.
  • Adoptive transfer of MCMV-immune splenocytes or CD4+ T cells significantly reduced MCMV levels in the brain within 7 days.
  • Pre-emptive administration of CMV-immune splenocytes prevented MCMV entry into the brain of immunocompromised mice.

Conclusions:

  • Adoptive transfer of CMV-immune T cells is a promising strategy for treating established neurotropic CMV infections.
  • This immunotherapy can rapidly clear CMV from the brain and prevent its central nervous system dissemination.
  • Systemic adoptive T-cell transfer offers a potential rapid and effective approach for preventing and treating CMV encephalitis in immunocompromised patients.